Skip to main content
S&P 5007,744.06+0.33%DOW52,177.69+1.08%NASDAQ26,713.03+0.08%BTC$82,229.00+0.84%ETH$2,438.91+0.85%GOLD$4,174.70+0.11%OIL$96.01-0.51%
Smart Investors Daily
SID Premium
Protalix BioTherapeutics, Inc. Common Stock logo

NASDAQ · PLX

Protalix BioTherapeutics, Inc. Common Stock

Healthcare · Biotechnology

$2.70

Up+$0.09 (+3.45%)

Updated Oct 16, 2026, 3:32 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
146.37M
P/E ratio
26.75
Dividend yield
0.00%
52-week range
$1.88 – $2.98
Volume
1.14M
Avg. volume
789.76K

Price performance · PLX

PLX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 15, 2026

PLX closed at $2.70 after 21 trading sessions, up 0.00% for the selected period.

Last close
$2.70
Period change
+0.00%
Period low
$2.61
Period high
$2.84
Daily close
View OHLC price history
PLX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 15, 2026$2.63$2.75$2.62$2.701.14M
Oct 14, 2026$2.73$2.775$2.61$2.611.53M
Oct 13, 2026$2.80$2.80$2.735$2.75967.79K
Oct 12, 2026$2.75$2.80$2.71$2.78717.14K
Oct 9, 2026$2.70$2.785$2.69$2.781.2M
Oct 8, 2026$2.68$2.71$2.61$2.70972.85K
Oct 7, 2026$2.70$2.765$2.68$2.71794.73K
Oct 6, 2026$2.74$2.76$2.65$2.73934.74K
Oct 5, 2026$2.68$2.74$2.65$2.71984.06K
Oct 2, 2026$2.70$2.72$2.64$2.71947.41K
Oct 1, 2026$2.77$2.77$2.60$2.681.59M
Sep 30, 2026$2.69$2.815$2.68$2.76836.26K
Sep 29, 2026$2.69$2.735$2.6803$2.69898.56K
Sep 28, 2026$2.71$2.72$2.61$2.69832.82K
Sep 25, 2026$2.76$2.775$2.70$2.72386.03K
Sep 24, 2026$2.78$2.8167$2.73$2.75302.7K
Sep 23, 2026$2.84$2.8495$2.765$2.80586.41K
Sep 22, 2026$2.75$2.84$2.75$2.84854.9K
Sep 21, 2026$2.71$2.78$2.69$2.75471.38K
Sep 18, 2026$2.68$2.715$2.66$2.691.25M
Sep 17, 2026$2.71$2.725$2.68$2.70321.89K

Latest PLX news

The latest Smart Investors Daily articles mentioning PLX.

Stock researchCompany · Overview

PLX research

Overview

Company profile and research snapshot.

Company profile

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PLX recent ratings
DateFirmRatingTarget
Sep 9, 2026HC Wainwright & Co.Buy—
Mar 19, 2026HC Wainwright & Co.Buy—
Nov 21, 2025HC Wainwright & Co.Buy—
Feb 3, 2025HC Wainwright & Co.Buy—
Nov 14, 2023HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 11, 2026

3 Oil And Gas Stocks to Watch as Supply Shock Risks Rise

Energy markets are running on a thinner safety cushion as emergency oil releases eat into strategic reserves and new buyers in Asia chase limited barrels. That mix creates real risk for future supply shocks and sharp price swings, along with potential openings for investors who understand which integrated oil and gas producers could benefit. This piece explains that backdrop and then highlights 3 stocks from our screener that are closely tied to this story. The three integrated producers...

Yahoo · Sep 8, 2026

Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By